TRD · Relapse monitoring
Close the relapse blind spot in treatment-resistant depression.
Treatment-resistant depression is defined by its tendency to come back. Around half of TRD patients relapse within 6 to 12 months, and most of those relapses are never caught in time, because the months between visits are unmonitored.
Relapse hides between visits
TRD patients across TMS, esketamine, and ketamine programs share the same maintenance-phase risk: the clinic has no visibility between appointments. The PHQ-9 by email reaches a minority, and the patients most at risk are the least likely to complete it. The result is a structural blind spot, not a failure of clinical care.
50%
of TRD patients relapse within 6 to 12 months
60%
of those relapses go undetected
48h
early-warning lead time from the passive signal
How Emobot monitors TRD relapse
Works across modalities
The same passive monitoring covers TRD patients whether they are on TMS, Spravato, or ketamine.
Continuous and objective
Daily multimodal signal instead of an occasional self-report, correlated with MADRS at r=0.89.
Catches the silent relapse
Detects deterioration about 48 hours before symptom-level worsening, including in patients who would never complete a survey.
Nudges patients back
When the signal shifts, the patient is prompted to reconnect before they fall out of care.
The evidence
- Validated across 11 studies with Yale, Harvard, Johns Hopkins, UCSD, McGill, Charité, and GHU Paris.
- 75% activation when the physician recommends it, versus 30 to 40% for PHQ-9 by email.
- On-device processing; only anonymized numerical output is transmitted.
Frequently asked questions
What is the relapse rate in treatment-resistant depression?
Approximately 50% of TRD patients relapse within 6 to 12 months, and about 60% of those relapses go undetected by the treating clinic until the patient disengages.
Why are TRD relapses missed?
Because the maintenance window between visits is unmonitored in standard care. Email-based PHQ-9 reaches only a minority, and depressive symptoms themselves reduce the likelihood that an at-risk patient completes it.
Does this replace the PHQ-9?
No. It is the continuous, objective data between PHQ-9 assessments. The PHQ-9 remains a periodic anchor; passive monitoring fills the long gaps in between.
Go deeper in the full guide: Passive Depression Monitoring: Clinical Guide
See it on a real patient case.
A 30-minute demo walks through the dashboard and how TRD patients show up in the data between visits.